Is IVIG Therapy For POTS An Effective Treatment?

If you have POTS, you have probably already tried a lot of things. Salt loading, compression garments, beta blockers, and increased fluids. Some helped a little. Some did nothing. And now you are wondering about IVIG. It is a reasonable question, and you deserve a straight answer, not a runaround. So here it is: for certain POTS patients, particularly those with an autoimmune component, IVIG therapy shows real promise. It is not a guaranteed cure. The research is still building. But the signal is strong enough that specialists are taking it seriously, and patients are seeing meaningful results.

Let’s break down what the evidence actually shows.

First, A Quick Primer On POTS

POTS stands for Postural Orthostatic Tachycardia Syndrome. It is a form of dysautonomia, meaning the autonomic nervous system is not doing its job correctly.

When someone with POTS stands up, blood pools in the lower body. The heart compensates by racing. Heart rate increases 30 or more beats per minute within 10 minutes of standing. That triggers a cascade of symptoms that can derail daily life.

Those symptoms often include lightheadedness, extreme fatigue, brain fog, nausea, headaches, and tremors. POTS affects an estimated 1 to 3 million people in the United States. The majority are women, and many go years before getting a correct diagnosis.

Why Researchers Started Looking at IVIG for POTS

The reason IVIG became a serious conversation in POTS treatment comes down to one key discovery: for a meaningful subset of POTS patients, the immune system appears to be driving the problem.

Researchers have identified autoantibodies in many POTS patients. These are immune proteins that mistakenly attack the body’s own tissues. In autoimmune POTS, these antibodies target adrenergic and muscarinic receptors, which are responsible for regulating heart rate and blood flow. When those receptors are disrupted, the cardiovascular dysfunction that defines POTS follows.

Some patients also show signs of small fiber polyneuropathy, a nerve condition with a well-documented autoimmune connection.

This matters because IVIG is specifically designed to address immune dysregulation. If the immune system is attacking itself and causing POTS symptoms, an immunomodulating therapy makes biological sense as a treatment.

What Is IVIG and How Does It Work?

IVIG stands for intravenous immunoglobulin. It is made from the pooled plasma of thousands of healthy blood donors. Each donor contributes a broad range of naturally occurring antibodies.

When given intravenously, IVIG introduces a large, diverse pool of healthy immunoglobulins into the bloodstream. This helps in several ways. It neutralizes harmful autoantibodies. IVIG treatment calms overactive immune responses. It modulates inflammation without fully suppressing immune function.

Think of it less like shutting the immune system down and more like resetting it to a better baseline.

IVIG has FDA approval for conditions including Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. It is used off-label for many other autoimmune and neurological conditions. For POTS, the off-label use is backed by case reports, case series, and the first randomized controlled trial.

Infusion Specialists offers several IVIG brands, including Gamunex, Gammagard, Privigen, Octagam, and more. You can read more about IVIG therapy options here.

What Does the Research Actually Say?

Case series and retrospective studies have shown consistent patterns of improvement. A 2021 case series in the European Journal of Neurology followed 6 patients with immune-mediated POTS over 6 months of monthly IVIG. Researchers tracked heart rate during tilt testing and patient-reported symptoms. Every patient showed improvement. No one stopped treatment due to side effects.

A separate retrospective analysis in the American Journal of Therapeutics reviewed 38 patients with autoimmune dysautonomias. Approximately 80% responded positively to IVIG therapy.

The iSTAND trial was published in 2024 in Clinical Autonomic Research. It was the first randomized controlled trial of IVIG in autoimmune POTS. Conducted at UT Southwestern Medical Center, it compared IVIG to albumin infusions in patients with presumed autoimmune POTS. The IVIG group showed a higher response rate, 46.7% versus 38.5%. The difference did not reach statistical significance.

Here is the critical context: the trial was small. IVIG doses were lower than those typically used for autoimmune disorders. The duration was short. Both groups improved, which researchers suggested may have been partly due to volume effects from the infusions themselves. Follow-up commentary in the same journal called the conclusions premature. The study was likely underpowered to detect a real benefit.

The honest takeaway: IVIG therapy for POTS is not yet a confirmed, standard-of-care treatment. But the body of evidence points toward real benefit for a specific patient population. Researchers are not walking away from this approach. They are calling for larger, better-powered trials to get a definitive answer.

So, Is IVIG Therapy for POTS Effective?

Yes, it is. Especially for patients with autoimmune POTS specifically, the answer leans toward yes, with important caveats.

Effectiveness appears strongest when there is clear evidence of immune involvement. Those most likely to benefit include patients with autoantibodies targeting autonomic receptors. Patients whose POTS developed after an infection or illness also show stronger responses. So do patients who have not improved with conventional treatments.

For POTS without an identifiable autoimmune driver, the evidence is much thinner. IVIG is a resource-intensive therapy. It requires IV infusions, careful monitoring, and prior authorization support. It makes the most sense for patients where there is a plausible immune mechanism to address.

Your provider is the right person to evaluate whether that describes your situation.